Background
Methods
Data source
Cohort definition
Primary & secondary endpoints
Disease / Procedure | Specification | ICD / OPS coding |
---|---|---|
Extracorporal liver support therapy | “Liver dialysis” | OPS 8–858 |
Liver transplantation | Liver transplantation (all variants) | OPS 5–504 |
Evaluation for liver transplantation | ||
“Evaluation & no waiting list” | Complete evaluation, without inclusion of a patient on an organ transplantation waiting list | OPS 1–920.04 |
Partial evaluation without inclusion of a patient on an organ transplantation waiting list | OPS 1–920.14 | |
“Evaluation & waiting list” | Complete evaluation, with inclusion of a patient on an organ transplantation waiting list | OPS 1–920.24 |
“Reevaluation” | Re-evaluation, with inclusion or retention of a patient on an organ transplantation waiting list | OPS 1–920.34 |
Re-evaluation, with removal of a patient from an organ transplantation waiting list | OPS 1–920.44 |
“Primary liver failure group” | |
Alcoholic liver disease | ICD K70 |
Liver failure, not elsewhere classified (includes fulminant liver failure) | ICD K72 |
Fibrosis and cirrhosis of the liver | ICD K74 |
Other diseases of the liver | ICD K76 |
Other diseases of the biliary tract | ICD K83 |
Malignant neoplasm of liver and intrahepatic bile ducts | ICD C22 |
Congenital malformations of the gallbladder, bile ducts and liver | ICD Q44 |
Disorders of mineral metabolism (includes M. Wilson, Hemochromatosis) | ICD E83 |
Other metabolic disorders | ICD E88 |
Other venous embolism and thrombosis (including Budd-Chiari-Syndrome) | ICD I82 |
“Secondary liver failure group” – Cardiac surgery patient population | |
Operative external circulation (when using the heart-lung machine) | OPS 8–851 |
Operations on valves and septa of the heart and cardiac vessel | OPS 5–35 |
Surgery on the coronary vessels | OPS 5–36 |
Rhythm surgery and other operations on the heart and pericardium | OPS 5–37 |
Resection and replacement (interposition) at the aorta | OPS 5–384 |
Patient involvement
Reporting guidelines
Statistical analysis
Results
Primary endpoints: annual incidences & in- hospital mortality rates
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | Overall 2007–2015 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
All ELS patients | |||||||||||
n | 314 | 311 | 390 | 377 | 287 | 270 | 255 | 294 | 388 | 2886 | |
Mortality (%) | 57.32 | 55.63 | 46.41 | 46.42 | 52.61 | 55.18 | 61.18 | 50.00 | 44.84 | 51.49 | |
Annual incidence | (n/100.000) | 0.39 | 0.39 | 0.48 | 0.47 | 0.36 | 0.34 | 0.32 | 0.36 | 0.47 | 0.43 |
Sex | |||||||||||
Male | n | 211 | 191 | 247 | 238 | 190 | 176 | 171 | 179 | 219 | 1822 |
Mortality (%) | 60.19 | 57.59 | 51.01 | 50.84 | 55.26 | 54.55 | 62.57 | 55.87 | 58.90 | 56.04 | |
Female | n | 103 | 120 | 143 | 139 | 97 | 94 | 84 | 115 | 169 | 1064 |
Mortality (%) | 51.46 | 52.50 | 38.46 | 38.85 | 47.42 | 56.38 | 58.33 | 40.87 | 26.63 | 43.70 | |
Age groups | |||||||||||
0–20 years | n | 17 | 10 | 25 | 17 | 16 | 10 | 5 | 32 | 84 | 216 |
20–40 years | n | 41 | 30 | 49 | 38 | 37 | 28 | 29 | 29 | 38 | 319 |
40–60 years | n | 126 | 137 | 180 | 189 | 130 | 111 | 109 | 109 | 134 | 1225 |
60–80 years | n | 124 | 126 | 129 | 126 | 99 | 109 | 109 | 121 | 124 | 1067 |
>80 years | n | 6 | 8 | 7 | 7 | 5 | 12 | 3 | 3 | 8 | 59 |
Secondary endpoints: ELS & liver transplantation
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2007–2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Liver transplantations, n (%) | 49 (15.6) | 38 (12.2) | 55 (14.1) | 71 (18.8) | 49 (17.1) | 30 (11.1) | 32 (12.5) | 18 (6.1) | 18 (4.6) | 360 (12.4) |
In-hospital Mortality | 19 (38.8) | 22 (57.9) | 17 (30.9) | 23 (32.4) | 15 (30.6) | 8 (26.7) | 20 (62.5) | 4 (22.2) | 7 (38.9) | 135 (37.5) |
Evaluation & waiting list, n (%) | 13 (4.14) | 8 (2.57) | 24 (6.15) | 28 (7.43) | 26 (9.06) | 19 (7.04) | 9 (3.53) | 9 (3.06) | 7 (1.80) | 143 (4.95) |
Evaluation & no waiting list, n (%) | 0 | 6 (1.92) | 2 (0.51) | 5 (1.33) | 1 (0.35) | 3 (1.11) | 1 (0.39) | 4 (1.36) | 3 (0.77) | 25 (0.87) |
Re-Evaluation, n (%) | 3 (0.96) | 1 (0.32) | 6 (1.54) | 2 (0.53) | 3 (1.05) | 0 | 3 (1.18) | 1 (0.34) | 0 | 19 (0.66) |
ELS in primary liver dysfunction versus secondary liver dysfunction (in the context of cardiac surgery)
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2007–2015 | |
---|---|---|---|---|---|---|---|---|---|---|
Overall ELS therapies, n | 314 | 311 | 390 | 377 | 287 | 270 | 255 | 294 | 388 | 2886 |
Mortality (%) | 57.32 | 55.63 | 46.41 | 46.42 | 52.61 | 55.18 | 61.18 | 50.00 | 44.84 | 51,49 |
Primary ALS, n (% of all ELS) | 152 (48.41) | 156 (50.16) | 182 (46.67) | 189 (50.13) | 132 (45.99) | 97 (35.93) | 102(40.00) | 92 (31.29) | 131 (33.76) | 1233 (42.72) |
Mortality (%) | 48,03 | 42,95 | 32,42 | 30,16 | 36,36 | 44,33 | 55,88 | 42,39 | 44,27 | 40,63 |
Secondary ALS, n (% of all ELS) | 115 (36,62) | 129 (41,48) | 126 (32,31) | 139 (36,87) | 121 (42,16) | 157 (58,15) | 140 (54,90) | 190 (64,63) | 196 (50,52) | 1313 (45,50) |
Mortality (%) | 80,00 | 75,19 | 69,84 | 62,59 | 77,69 | 64,97 | 69,29 | 54,74 | 69,90 | 68,39 |